Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Welcome and Introduction to Vi3C

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Use of Statins in CLL/SLL

High-Fiber Diet May Slow Disease Progression to Multiple Myeloma

Omission of Endocrine Therapy in Estrogen Receptor-Low Early-Stage Breast Cancer

Childhood Exposure to Bacterial Toxin May Trigger Early Onset Colorectal Cancer

WHI Funding Future Unclear